Skip to content

Clinical study for prevention of esophageal stricture after endoscopic submucosal dissection for large area early esophageal cancer by autologous skin-grafting surgery

Clinical study for prevention of esophageal stricture after endoscopic submucosal dissection for large area early esophageal cancer by autologous skin-grafting surgery

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025968
Enrollment
Unknown
Registered
2019-09-16
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early esophageal cancer

Interventions

observation group:autologous skin-grafting surgery
control group:fully covered esophageal stent

Sponsors

Chinese PLA General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Early esophageal cancer patients; 2. transverse diameter of the lesion > circumference of esophagus 1/2, longitudinal diameter of the lesion > 3cm; 3. preoperative evaluation of lesion invasive depth does not exceed the superficial layer of submucosa, that is < 200um; 4. the whole lesion can be dissected completely; 5. aged between 20 and 80 years old; 6. The patient agreed to receive ESD and ASGS.

Exclusion criteria

Exclusion criteria: (1) Patients with contraindications of ESD andgeneral anesthesia: eg. coagulation dysfunction, liver and kidney dysfunction, cardiopulmonary dysfunction and malignant arrhythmia; (2) patients who have undergone surgery and radiotherapy; (3) patients with dysphagia of esophageal motility; (4) patients who refuse ESD and autologous skin-grafting surgery; (5) women in pregnancy or lactation; (6) lymph node metastasis in preoperative assessment.

Design outcomes

Primary

MeasureTime frame
esophageal stenosis;

Secondary

MeasureTime frame
Mellow - Pinkas score;

Countries

China

Contacts

Public ContactLinghu Enqiang

Chinese PLA General Hospital

linghuenqiang@vip.sina.com+86 13501233558

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026